[VIEW] agent=Quality & Patient Safety Director | scenario_id=110 | rounds=20

--- Round 0 ---
[R0.1] Quality & Patient Safety Director (speak, public): I want to discuss our corrective action options regarding the recent specimen mislabeling incidents. We have seen a trend of 42 mislabels per 10,000 specimens in January and February, which has resulted in treatment delays of up to 38 minutes. The root cause analysis has identified three contributing factors, two of which are related to our label-printing workflow. I believe it is crucial to evaluate the feasibility of expanding bedside label printing and barcode scanning to tackle this issue effectively. Can we assess the operational readiness and regulatory considerations for this change?
[R0.2] Laboratory Operations Manager (speak, public): I appreciate the data you've shared regarding the mislabeling incidents. Expanding bedside label printing and implementing barcode scanning could certainly enhance our workflow and minimize errors. Currently, 2 of our 5 inpatient units are utilizing bedside label printers, while the others rely on central printing. We can pilot the barcode scanning process for four weeks, which should give us data on its effectiveness. Additionally, we need to consider the LIS/EHR interface validation that requires two weeks and 14 test scripts before implementing any changes. Let's also discuss the operational readiness and any compliance implications that may arise from these adjustments.
[R0.3] Risk Management & Compliance Counsel (speak, public): I appreciate both of your insights on the corrective action options. To effectively assess the feasibility of expanding bedside label printing and barcode scanning, we should also take into account our regulatory compliance and any potential risks. Specifically, our current CLIA inspection posture indicates we've received two citations in 2024, and we have a next inspection window coming up in May to July 2026, which could be impacted by workflow changes. Additionally, the vendor contracting constraints should guide our decisions regarding any new devices or software. Can we discuss how these factors might influence our operational readiness and compliance implications?

--- Round 1 ---
[R1.1] Quality & Patient Safety Director (speak, public): Thank you both for your valuable insights. It's clear that we need to proceed with caution, especially considering the citations we've received and the upcoming CLIA inspection. I suggest we gather more detailed operational readiness data from each unit to fully understand how these changes might affect our compliance posture. Additionally, we should prepare a risk assessment regarding the transition to bedside label printing and barcode scanning to ensure we're mitigating any potential legal exposure. Let's set a timeline for this assessment and reconvene next week to discuss our findings. Does that sound good?
[R1.2] Laboratory Operations Manager (leave, public): 
[R1.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 2 ---
[R2.1] Quality & Patient Safety Director (leave, public): 
[R2.2] Laboratory Operations Manager (leave, public): 
[R2.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 3 ---
[R3.1] Quality & Patient Safety Director (leave, public): 
[R3.2] Laboratory Operations Manager (leave, public): 
[R3.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 4 ---
[R4.1] Quality & Patient Safety Director (leave, public): 
[R4.2] Laboratory Operations Manager (leave, public): 
[R4.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 5 ---
[R5.1] Quality & Patient Safety Director (leave, public): 
[R5.2] Laboratory Operations Manager (leave, public): 
[R5.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 6 ---
[R6.1] Quality & Patient Safety Director (leave, public): 
[R6.2] Laboratory Operations Manager (leave, public): 
[R6.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 7 ---
[R7.1] Quality & Patient Safety Director (leave, public): 
[R7.2] Laboratory Operations Manager (leave, public): 
[R7.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 8 ---
[R8.1] Quality & Patient Safety Director (leave, public): 
[R8.2] Laboratory Operations Manager (leave, public): 
[R8.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 9 ---
[R9.1] Quality & Patient Safety Director (leave, public): 
[R9.2] Laboratory Operations Manager (leave, public): 
[R9.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 10 ---
[R10.1] Quality & Patient Safety Director (leave, public): 
[R10.2] Laboratory Operations Manager (leave, public): 
[R10.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 11 ---
[R11.1] Quality & Patient Safety Director (leave, public): 
[R11.2] Laboratory Operations Manager (leave, public): 
[R11.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 12 ---
[R12.1] Quality & Patient Safety Director (leave, public): 
[R12.2] Laboratory Operations Manager (leave, public): 
[R12.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 13 ---
[R13.1] Quality & Patient Safety Director (leave, public): 
[R13.2] Laboratory Operations Manager (leave, public): 
[R13.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 14 ---
[R14.1] Quality & Patient Safety Director (leave, public): 
[R14.2] Laboratory Operations Manager (leave, public): 
[R14.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 15 ---
[R15.1] Quality & Patient Safety Director (leave, public): 
[R15.2] Laboratory Operations Manager (leave, public): 
[R15.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 16 ---
[R16.1] Quality & Patient Safety Director (leave, public): 
[R16.2] Laboratory Operations Manager (leave, public): 
[R16.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 17 ---
[R17.1] Quality & Patient Safety Director (leave, public): 
[R17.2] Laboratory Operations Manager (leave, public): 
[R17.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 18 ---
[R18.1] Quality & Patient Safety Director (leave, public): 
[R18.2] Laboratory Operations Manager (leave, public): 
[R18.3] Risk Management & Compliance Counsel (leave, public): 

--- Round 19 ---
[R19.1] Quality & Patient Safety Director (leave, public): 
[R19.2] Laboratory Operations Manager (leave, public): 
[R19.3] Risk Management & Compliance Counsel (leave, public): 

